Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction

Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction

Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome resulting from the interaction between cardiac diseases, comorbidities and ageing. HFpEF is characterised by the activation of neurohormonal axes, namely of the renin-angiotensin-aldosterone system and the sympathetic...

Full description

Bibliographic Details
Main Authors:	Vincenzo Castiglione, Francesco Gentile, Nicolò Ghionzoli, Martina Chiriacò, Giorgia Panichella, Alberto Aimo, Giuseppe Vergaro, Alberto Giannoni, Claudio Passino, Michele Emdin
Format:	Article
Language:	English
Published:	Radcliffe Medical Media 2023-06-01
Series:	Cardiac Failure Review
Online Access:	https://www.cfrjournal.com/articleindex/cfr.2022.23

Similar Items

Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction
by: Chiara Borrelli, et al.
Published: (2019-09-01)

Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
by: Giuseppe Vergaro, et al.
Published: (2019-10-01)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
by: Giuseppe Vergaro, et al.
Published: (2021-02-01)

Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers
by: Michela Chianca, et al.
Published: (2022-07-01)

Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
by: Giuseppe Vergaro, et al.
Published: (2023-09-01)

Role of Imaging in Cardiomyopathies
by: Vincenzo Castiglione, et al.
Published: (2023-05-01)

The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism
by: Chiara Sanguinetti, et al.
Published: (2022-08-01)

Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
by: Paolo Morfino, et al.
Published: (2022-08-01)

Eligibility for vericiguat in a real‐world, contemporary heart failure population
by: Giuseppe Vergaro, et al.
Published: (2024-12-01)

Molecular Autopsy of Sudden Cardiac Death in the Genomics Era
by: Vincenzo Castiglione, et al.
Published: (2021-07-01)

Cardiovascular toxicity from therapies for light chain amyloidosis
by: Paolo Morfino, et al.
Published: (2023-07-01)

Prognostic value of reverse remodelling criteria in heart failure with reduced or mid‐range ejection fraction
by: Alberto Aimo, et al.
Published: (2021-08-01)

Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
by: Paolo Morfino, et al.
Published: (2023-04-01)

Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis
by: Alberto Aimo, et al.
Published: (2022-03-01)

The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers
by: Oriol Iborra-Egea, et al.
Published: (2022-07-01)

Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure
by: Francesco Gentile, et al.
Published: (2022-03-01)

Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction
by: Francesca Graziani, et al.
Published: (2021-04-01)

Intracoronary Delivery of Mitochondria to Prevent Ischemia–Reperfusion Injury
by: Alberto Aimo, MD, et al.
Published: (2020-02-01)

Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction
by: Elisabeth A. Jalink, et al.
Published: (2024-01-01)

Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction
by: Heidi Budde, et al.
Published: (2022-07-01)

Neurohormones in Vasovagal Syncope: Are They Important?
by: Noah N. Williford, et al.
Published: (2019-06-01)

HYPOTHALAMIC NEUROHORMONES AND IMMUNE RESPONSES
by: J. Luis eQuintanar, et al.
Published: (2013-08-01)

Pirfenidone in heart failure with preserved ejection fraction—rationale and design of the PIROUETTE trial
by: Lewis, G, et al.
Published: (2019)

Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development
by: Edoardo Gronda, et al.
Published: (2020-12-01)

Tissue Characterization in Cardiac Amyloidosis
by: Veronica Musetti, et al.
Published: (2022-11-01)

Shared and unique characteristics of metabolic syndrome in psychotic disorders: a review
by: Luigi F. Saccaro, et al.
Published: (2024-03-01)

Combination therapy using tafamidis and neurohormonal blockers for cardiac amyloidosis and a reduced ejection fraction: a case report
by: Teruhiko Imamura, et al.
Published: (2022-07-01)

Heart Failure With Preserved Ejection Fraction: A Review of Cardiac and Noncardiac Pathophysiology
by: Andreas B. Gevaert, et al.
Published: (2019-05-01)

Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis
by: Chao Ma, et al.

A Cross-Correlational Analysis between Electroencephalographic and End-Tidal Carbon Dioxide Signals: Methodological Issues in the Presence of Missing Data and Real Data Results
by: Maria Sole Morelli, et al.
Published: (2016-10-01)

The Neurohormonal Overactivity Syndrome in Heart Failure
by: Andrew Xanthopoulos, et al.
Published: (2023-01-01)

Neurohormonal aspects of sexual drive in women
by: M. V. Mazurkevich, et al.
Published: (2015-04-01)

Neurohormonal aspects of sexual drive in women
by: M. V. Mazurkevich, et al.
Published: (2015-04-01)

Neurohormones in insect stress: A review
by: Perić-Mataruga Vesna, et al.
Published: (2006-01-01)

Contribution of the Lung to the Genesis of Cheyne‐Stokes Respiration in Heart Failure: Plant Gain Beyond Chemoreflex Gain and Circulation Time
by: Alberto Giannoni, et al.
Published: (2019-07-01)

Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis
by: Joanna M Bilak, et al.
Published: (2022-07-01)

Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction: State of the Art and Prospects for the Future
by: Sara Lopes Fernandes, et al.
Published: (2019-11-01)

Heart failure with preserved ejection fraction in elderly. From pathophysiology to treatment: an unresolved problem
by: Matteo Beltrami, et al.
Published: (2019-05-01)

Prediction of the Chemoreflex Gain by Common Clinical Variables in Heart Failure.
by: Gianluca Mirizzi, et al.
Published: (2016-01-01)

Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient
by: Giuseppe Vergaro, MD, PhD, et al.
Published: (2021-03-01)